CRISPR Therapeutics (NASDAQ:CRSP) Trading 3.4% Higher

CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) was up 3.4% during trading on Tuesday . The stock traded as high as $59.18 and last traded at $57.54. Approximately 674,696 shares changed hands during mid-day trading, a decline of 62% from the average daily volume of 1,754,096 shares. The stock had previously closed at $55.65.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Needham & Company LLC lowered their target price on shares of CRISPR Therapeutics from $90.00 to $88.00 and set a "buy" rating on the stock in a research report on Thursday, May 9th. Mizuho increased their price objective on CRISPR Therapeutics from $82.00 to $99.00 and gave the company a "buy" rating in a research note on Wednesday, March 6th. Oppenheimer cut their price target on CRISPR Therapeutics from $102.00 to $95.00 and set an "outperform" rating for the company in a report on Friday. Royal Bank of Canada raised their price objective on CRISPR Therapeutics from $57.00 to $66.00 and gave the stock a "sector perform" rating in a report on Thursday, February 22nd. Finally, Cantor Fitzgerald reiterated a "neutral" rating on shares of CRISPR Therapeutics in a research note on Thursday, May 9th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $73.93.

CRISPR Therapeutics Trading Up 0.1 %

The business has a 50 day simple moving average of $63.51 and a two-hundred day simple moving average of $65.22. The stock has a market cap of $4.73 billion, a price-to-earnings ratio of -20.48 and a beta of 1.80.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by ($0.08). The company had revenue of $0.50 million for the quarter, compared to analysts' expectations of $25.53 million. During the same quarter in the previous year, the company earned ($0.67) earnings per share. CRISPR Therapeutics's quarterly revenue was down 99.5% compared to the same quarter last year. Research analysts anticipate that CRISPR Therapeutics AG will post -5.98 EPS for the current fiscal year.

Insider Transactions at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 19,582 shares of the business's stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $59.91, for a total transaction of $1,173,157.62. Following the completion of the transaction, the chief executive officer now directly owns 208,122 shares of the company's stock, valued at approximately $12,468,589.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other CRISPR Therapeutics news, CFO Raju Prasad sold 3,524 shares of the business's stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $72.69, for a total transaction of $256,159.56. Following the sale, the chief financial officer now directly owns 6,476 shares in the company, valued at approximately $470,740.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Samarth Kulkarni sold 19,582 shares of the business's stock in a transaction on Monday, April 15th. The stock was sold at an average price of $59.91, for a total value of $1,173,157.62. Following the completion of the sale, the chief executive officer now directly owns 208,122 shares in the company, valued at approximately $12,468,589.02. The disclosure for this sale can be found here. In the last three months, insiders have sold 83,992 shares of company stock worth $6,132,335. 4.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of CRSP. Riggs Asset Managment Co. Inc. grew its holdings in shares of CRISPR Therapeutics by 66.7% in the 1st quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company's stock worth $34,000 after acquiring an additional 200 shares during the last quarter. Blue Trust Inc. acquired a new stake in CRISPR Therapeutics during the 4th quarter worth about $32,000. Bourgeon Capital Management LLC lifted its stake in CRISPR Therapeutics by 1,000.0% during the fourth quarter. Bourgeon Capital Management LLC now owns 550 shares of the company's stock valued at $34,000 after buying an additional 500 shares in the last quarter. NBC Securities Inc. increased its position in shares of CRISPR Therapeutics by 257.6% in the first quarter. NBC Securities Inc. now owns 608 shares of the company's stock worth $41,000 after acquiring an additional 438 shares in the last quarter. Finally, Principal Securities Inc. purchased a new position in shares of CRISPR Therapeutics in the fourth quarter worth approximately $41,000. 69.20% of the stock is owned by institutional investors and hedge funds.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.